Samsung Cuts U.S. Consumer Electronics Jobs as Headquarters Moves to Texas 
Gold Climbs Above $4,000 as Middle East Tensions and Fed Outlook Drive Safe-Haven Demand 
European Stocks Slip as Earnings, UK Inflation and ECB Decision Keep Investors on Edge 
GM Q2 Earnings Beat Estimates as General Motors Raises 2026 Profit Outlook 
South Korea Q2 GDP Beats Forecasts as AI Chip Exports Drive Growth 
Rubio Rejects AI ‘Kill Switch’ Claims as U.S. Defends American Technology Abroad 
US Stock Exchanges Face Earnings Test as Trading Boom Meets Crypto Competition 
US Dollar Climbs to Weekly High as Middle East Tensions Lift Treasury Yields and Safe-Haven Demand 
Macquarie Names Greg Ward as CEO, Signaling Stability and Strategic Continuity 
Morgan Stanley Downgrades Adobe, Workday as AI Transition Raises Growth Concerns 
Alphabet Q2 Earnings Beat Estimates as AI Spending, Google Cloud Growth Fuel Outlook 
Pakistan Seeks $10 Billion U.S. Exchange Stabilization Fund to Boost Forex Reserves 
Why Maruti Suzuki Is Losing Market Share in India as SUVs and Premium Features Gain Popularity 
OpenAI Australia Data Center Switches Cooling Strategy After Recycled Water Plan Fails 
SpaceX Q2 Earnings on Aug. 4 Set Stage for Historic Insider Share Unlock 
Elon Musk Fuels SpaceX-Tesla Merger Speculation After Earnings Call 
Nvidia Reveals 9.3% Stake in AI Cloud Firm Nebius Following $2 Billion Investment 
Johnson & Johnson acquires Abiomed medical device technology company that develops and manufactures temporary external and implantable mechanical circulatory support devices such as the heart pump. The company invested $16.6 million in the acquisition deal.
Johnson & Johnson revealed its latest investment on Tuesday, Nov. 1, and it was described as its biggest purchase in almost six years. The buyout was a strategic move as the company is looking to bolster its cardiovascular business.
It was noted that the decision was made at a time when Johnson & Johnson was spinning off its consumer health business unit so it could focus on works related to pharmaceuticals and medical devices. The addition of Abiomed to its portfolio through the acquisition deal is expected to scale up its medical device division.
As part of the agreement, the company will pay $380 for each Abiomed share. It will also hand out another $35 per share in cash if the Danvers, Massachusetts-headquartered medical device maker achieves new commercial and clinical milestones, as per CNBC.
Abiomed is known to develop heart pumps and other technology for the treatment of coronary artery disease and heart failure. Its Impella heart pump device is typically used for patients suffering from severe coronary artery disease.
This Johnson & Johnson and Abiomed acquisition agreement is expected to be completed by early next year. Once done, it will help J&J broaden its position as a thriving cardiovascular innovator while also building its medical device segment.
“The addition of Abiomed is an important step in the execution of our strategic priorities and our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech,” Johnson & Johnson’s chief executive officer, Joaquin Duato, said in a press release.
The CEO added, “We have committed to enhancing our position in MedTech by entering high-growth segments. The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders.”
Finally, Johson & Johnson said that Abiomed will be placed under its medical technology unit but that, despite the acquisition, it will continue to operate as a standalone business.
